



International Statin Usage Among Seniors: A Global Comparison

The United States does indeed have high rates of statin usage among seniors, but international data reveals significant variation across countries in how statins are prescribed to older adults.

US Statin Usage Among Seniors

In the United States, statin usage among seniors is substantial and has increased dramatically over the past decades. **By 2011-2012, approximately 28% of adults aged 45 and older were using cholesterol-lowering medications, with usage rates reaching 48% among those 75 and older.** Some studies indicate even higher rates, with **nearly 70.8% of adults aged 65 and older using statins in 2011-2012**, though this figure may reflect specific high-risk populations rather than the general elderly population.^{[1] [2]}

The increase has been particularly pronounced in the oldest age groups. Among adults aged 75 and older, statin use increased from **11.7% in 1988-1994 to 43.7% in 2005-2008**, representing one of the most dramatic medication adoption trends in geriatric medicine.^[1]

International Comparison by Country

Canada

Canadian statin usage among seniors shows more conservative prescribing patterns compared to the US. **About 27% of Canadian seniors (65+) with diagnosed ischemic heart disease were receiving statins as of 2016-2017.** In British Columbia specifically, **47% of men and 33% of women over 70 were taking statins in 2020**, indicating substantial gender differences in prescribing patterns.^{[3] [4]}

A 2015 analysis found that **37.7% of Canadians aged 40-75 would be eligible for statin therapy under Canadian guidelines, compared to 33.0% under US guidelines**, suggesting different risk assessment approaches between the countries.^[5]

Australia

Australian data from the Department of Veterans Affairs shows that **statin utilization among elderly veterans increased from 17% in 2001 to 35% in 2012.** This population is predominantly older, making it particularly relevant for senior comparisons. **More than 40% of older adults in Australia used statins by 2016**, with uptake dependent on individual demographics and comorbidities.^{[6] [7]}

United Kingdom

The UK shows some of the highest statin usage rates internationally among the very elderly. **Among adults aged 80 and older, prevalent statin use reached 49.3% by 2011-2015**, representing a dramatic increase from **9.9% in 2001-2005**. However, the UK also shows high rates of statin discontinuation, with **deprescribing occurring at 5.6% per year overall and increasing substantially with age**.^[8]

European Countries

France demonstrates concerning patterns of potential statin overuse among the elderly. A 2017 study found that **60.7% of French adults aged 80 and older had potential statin overuse according to clinical guidelines**, with **79% of nursing home residents showing potential overuse**.^{[9] [10]}

Sweden shows more moderate usage rates, with **35% of all elderly receiving statins in 2019**. Usage varies by age and gender, with **43% of men aged 75-84 receiving statins compared to 25% of women aged 85 and older**.^[11]

Netherlands data from 2008 showed **15.2% statin usage among adults aged 80 and older**, representing the lower end of international usage rates. Dutch prescribing appeared more conservative, with lower dosages typically prescribed to elderly patients.^{[12] [13]}

Finland experienced one of the most dramatic increases in elderly statin use, with **prevalence among those 65-74 reaching 31% by 2005**. The **largest relative increase was observed among those aged 75 and older, with a 14-fold increase between 1995-2005**.^[14]

Denmark showed the **highest increase in statin utilization among European countries**, though specific usage percentages for seniors were not detailed in available data.^[15]

Japan

Japanese studies focus more on clinical outcomes than population usage rates, but indicate **substantial statin use among older adults for primary prevention**. Research suggests **statin use for primary prevention is feasible in patients aged 75 to 85 years**, particularly those with comorbidities.^{[16] [17]}

Key International Patterns

Several important trends emerge from the international data:

Age-Related Prescribing Patterns: Most countries show **decreasing statin usage with advancing age**, particularly after 80 years. This reflects both clinical caution about benefits in the very elderly and concerns about polypharmacy.

Gender Differences: **Men consistently receive statins at higher rates than women** across most countries, likely reflecting higher baseline cardiovascular risk profiles.

Geographic Variation: European countries generally show more conservative prescribing patterns compared to North America and Australia, possibly reflecting different healthcare

systems and clinical guidelines.

Overuse Concerns: Several countries, particularly France, show evidence of **potential statin overuse among the elderly**, with many patients not meeting clinical guideline criteria for treatment.

Clinical Context and Guidelines

The variation in international usage rates reflects ongoing **uncertainty in clinical guidelines about statin use in the very elderly**. The **2018 US ACC/AHA guidelines provide limited direction for adults over 75**, while **European guidelines are even more conservative, defining older adults as those ≥ 70 years rather than ≥ 75 years**.^[18]

Recent evidence suggests that **statin benefits may extend beyond age 75**, but **randomized trial data remains limited for the very elderly**, leading to conservative prescribing in many healthcare systems.^{[19] [20]}

The US appears to have among the highest senior statin usage rates globally, with nearly half of those 75 and older receiving these medications. However, this comes with ongoing debates about appropriate prescribing thresholds and the balance between cardiovascular benefits and potential risks in very elderly populations.

```
<div style="text-align: center">✖</div>
```

1. <https://nchstats.com/statistics-on-statin-use/>
2. <https://www.cdc.gov/nchs/products/databriefs/db177.htm>
3. <https://www.ti.ubc.ca/2021/06/13/130-evidence-for-statins-in-people-over-70/>
4. <https://www.nicenet.ca/articles/cholesterol-and-older-adults>
5. <https://www.ahajournals.org/doi/10.1161/JAHA.114.001758>
6. <https://clinmedjournals.org/articles/ijcc/ijcc-1-016.php?jid=ijcc>
7. <https://www.sciencedirect.com/science/article/abs/pii/S1933287418304227>
8. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5669477/>
9. <https://pubmed.ncbi.nlm.nih.gov/31317420/>
10. <https://pubmed.ncbi.nlm.nih.gov/33949722/>
11. <https://uu.diva-portal.org/smash/get/diva2:1913689/FULLTEXT01.pdf>
12. <https://pure.amsterdamumc.nl/en/publications/statin-prescribing-in-the-elderly-in-the-netherlands-a-pharmacy-d>
13. <https://pubmed.ncbi.nlm.nih.gov/20583852/>
14. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2526244/>
15. <https://bmjopen.bmj.com/content/6/3/e010500>
16. <https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0295052>
17. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10691679/>
18. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9830552/>

19. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12098413/>
20. <https://evidence.nihr.ac.uk/alert/older-people-who-take-statins-live-longer-in-better-health/>
21. <https://www.goodrx.com/healthcare-access/research/statin-fills-across-the-united-states>
22. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4890684/>
23. <https://www.ahajournals.org/doi/10.1161/JAHA.118.008546>
24. <https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.779044/full>
25. <https://www.lipid.org/lipid-spin/potpourri-2016/statin-therapy-very-elderly-80-ascvd-balancing-benefits-and-risks>
26. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9944594/>
27. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11043821/>
28. <https://www.sciencedirect.com/science/article/abs/pii/S0146280622002262>
29. <https://www.ucsf.edu/news/2015/04/125236/statin-use-elderly-would-prevent-disease-could-carry-considerable-side-effects>
30. <https://www.sciencedirect.com/science/article/abs/pii/S0953620517305101>
31. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10203693/>
32. <https://www.sciencedirect.com/science/article/pii/S2666667724000321>
33. <https://www.japi.org/article/japi-73-5-e1>
34. <https://www.aafp.org/pubs/afp/issues/2019/1215/p742.html>
35. <https://healthpolicy.fsi.stanford.edu/news/lower-doses-statins-just-effective-older-adults-who-are-greater-risk-side-effects-cholesterol>
36. <https://pubmed.ncbi.nlm.nih.gov/12772016/>
37. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10852509/>
38. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6976171/>
39. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4179894/>
40. <https://www.sciencedirect.com/science/article/abs/pii/S0146280621000955>
41. <https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwaf357/8172996>
42. <https://www150.statcan.gc.ca/n1/pub/82-003-x/2016001/article/14305-eng.htm>
43. <https://medicinetoday.com.au/mt/2024/march/regular-series/lipid-lowering-therapy-older-people-update-prescribing>
44. <https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-19/management-of-dyslipidaemia-in-the-elderly>
45. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2628968>
46. <https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0223515>
47. <https://www.cihi.ca/en/changes-in-drug-prescribing-to-seniors-in-canada>
48. <https://academic.oup.com/braincomms/article/6/3/fcae195/7687729>
49. <https://heart.bmj.com/content/110/21/1277>
50. <https://www.euractiv.com/section/health-consumers/news/patented-drugs-double-the-cost-of-fighting-heart-disease-in-france/>
51. [https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762\(24\)00053-X/fulltext](https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762(24)00053-X/fulltext)
52. <https://pubmed.ncbi.nlm.nih.gov/39676595/>

53. <https://www.tctmd.com/news/statins-effective-primary-prevention-old-and-very-old>
54. <https://academic.oup.com/ageing/article/47/2/220/4237359>
55. <https://www.nature.com/articles/s41598-024-53252-4>
56. <https://firstwordpharma.com/story/2168965>
57. <https://www.pharmacymagazine.co.uk/clinical/value-of-statins-in-the-elderly-confirmed>
58. <https://ui.adsabs.harvard.edu/abs/2023PLoS...1895052F/abstract>
59. <https://www.bmj.com/content/363/bmj.k4700>
60. https://www.ahajournals.org/doi/10.1161/circoutcomes.6.suppl_1.A77?doi=10.1161%2Fcircoutcomes.6.suppl_1.A77
61. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9648819/>
62. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10828417/>
63. <https://pmc.ncbi.nlm.nih.gov/articles/PMC1885064/>
64. <https://www.sciencedirect.com/science/article/pii/S2666776223001187>
65. <https://pubmed.ncbi.nlm.nih.gov/29310996/>
66. <https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1742-7843.2009.00494.x>
67. <https://www.revespcardiol.org/en-persistence-with-statins-in-primary-articulo-S1885585717302001>
68. https://kce.fgov.be/sites/default/files/2021-11/KCE_306_Statins_primary_prevention_Report.pdf
69. https://www.academia.edu/22240755/The_Nordic_countries_as_a_cohort_in_pharmacoepidemiology
70. <https://www.sciencedirect.com/science/article/pii/S0939475323003836>
71. <https://www.sciencedirect.com/science/article/pii/S1544319125001244/pdf?md5=0c6943dffc6e62d04611c0828593c8aa&pid=1-s2.0-S1544319125001244-main.pdf>
72. [https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762\(23\)00043-1/fulltext](https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762(23)00043-1/fulltext)
73. <https://ppl-ai-code-interpreter-files.s3.amazonaws.com/web/direct-files/9b0e96f990e7afab6ca533ff045816f8/b3052441-039f-46fc-8fa8-8412aed8ffc0/6de2809c.csv>